KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) Tax Provisions (2017 - 2025)

Sarepta Therapeutics has reported Tax Provisions over the past 9 years, most recently at $4.6 million for Q4 2025.

  • For Q4 2025, Tax Provisions fell 64.69% year-over-year to $4.6 million; the TTM value through Dec 2025 reached $11.2 million, down 56.7%, while the annual FY2025 figure was $11.2 million, 56.62% down from the prior year.
  • Tax Provisions for Q4 2025 was $4.6 million at Sarepta Therapeutics, up from -$14.1 million in the prior quarter.
  • Over five years, Tax Provisions peaked at $64.0 million in Q1 2025 and troughed at -$43.3 million in Q2 2025.
  • A 5-year average of $3.3 million and a median of $2.4 million in 2022 define the central range for Tax Provisions.
  • Biggest five-year swings in Tax Provisions: skyrocketed 8528.26% in 2022 and later tumbled 3669.62% in 2025.
  • Year by year, Tax Provisions stood at $92000.0 in 2021, then skyrocketed by 8528.26% to $7.9 million in 2022, then plummeted by 164.49% to -$5.1 million in 2023, then skyrocketed by 353.64% to $13.0 million in 2024, then plummeted by 64.69% to $4.6 million in 2025.
  • Business Quant data shows Tax Provisions for SRPT at $4.6 million in Q4 2025, -$14.1 million in Q3 2025, and -$43.3 million in Q2 2025.